SCHEMBL3019345

SCHEMBL3019345

COc1ccc(-c2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4)CC3)n2)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.61
RECQL P46063 2/20 0.61
USP2 O75604 2/20 0.61
HSD17B10 Q99714 1/20 0.61
SMN1; SMN2 Q16637 6/20 0.60
ALDH1A1 P00352 3/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
KDM4E B2RXH2 1/20 0.52
NTSR1 P30989 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
POLB P06746 1/20 0.51
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020211 0.94 SMN1; SMN2 (0.60) MAPTRECQLUSP2HSD17B10SMN1; SMN2
SCHEMBL3015469 0.92 SMN1; SMN2 (0.60) MAPTRECQLUSP2HSD17B10SMN1; SMN2
SCHEMBL3002428 0.92 SMN1; SMN2 (0.64) MAPTRECQLUSP2HSD17B10SMN1; SMN2
SCHEMBL3015939 0.91 MAPT (0.59) MAPTRECQLUSP2HSD17B10SMN1; SMN2
SCHEMBL3001170 0.91 MAPT (0.67) MAPTRECQLUSP2HSD17B10SMN1; SMN2
SCHEMBL3019342 0.91 MAPT (0.62) MAPTRECQLUSP2HSD17B10SMN1; SMN2
SCHEMBL3009624 0.91 MAPT (0.60) MAPTRECQLUSP2HSD17B10SMN1; SMN2
SCHEMBL3008692 0.90 MAPT (0.58) MAPTRECQLUSP2HSD17B10SMN1; SMN2
SCHEMBL3011006 0.90 MAPT (0.61) MAPTRECQLUSP2HSD17B10SMN1; SMN2
SCHEMBL3011657 0.90 SMN1; SMN2 (0.75) MAPTRECQLUSP2HSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885RECQL 1564/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.